Direct costs for nonsurgical management of Chronic Pancreatitis in a tertiary care teaching hospital

Kamat, Nagesh and Pai, Ganesh C and Surulivelrajan, Mallayasamy and Kamath, Asha (2018) Direct costs for nonsurgical management of Chronic Pancreatitis in a tertiary care teaching hospital. Expert Review of Pharmacoeconomics & Outcomes Research, 18 (3). pp. 315-320. ISSN 1473-7167

[img] PDF
rms - 00007165.pdf - Published Version
Restricted to Registered users only

Download (1MB) | Request a copy


Background: Chronic pancreatitis (CP) is a leading cause of hospitalization among gastrointestinal diseases resulting in considerable financial burden to patients. However the direct costs for nonsurgical management in CP remains unexplored. Methods: A cross sectional study was carried out (2011–14) in the Department of Gastroenterology, Kasturba Hospital, Manipal, India. Demographic and clinical data on laboratory investigations, interventions and follow up were obtained from the medical records department. Item costs were derived from the hospital electronic billing section. Cost was expressed as median annual cost per patient. Results: 65 (male 48; 73.8%) patients were included. Their median age was 31 (range 12–68) years. The annual median (IQR) total cost per patient was INR 88,892 (70,550.5–116,004); [USD 1410(1119–1841); € 1155(916–1507)], comprising of INR 61,089 (39,102.5–90,360.5) [USD 970 (621–1434); € 793(508–1174)] for outpatient management and INR 32,450 (11,016–46,958) [USD 515 (175–745); €421(143–610)] for hospitalization. 69.5% of the treatment cost was attributed to outpatient treatment. Drugs contributed to 54%, hospitalization incurred 30.5%, investigations 12% and professional fees (3.5%) of the total cost. Pancreatic enzyme replacement therapy (PERT) cost contributed to three-quarters of drug therapy. Use of rabeprazole as against pantoprazole reduced the overall annual cost of therapy by 4%. Conclusions: This study depicts the first nonsurgical management of accrued direct costs associated with CP due to expensive medications. Due to the high cost for PERT, its usefulness needs proper validation by cost benefit analysis.

Item Type: Article
Uncontrolled Keywords: Chronic pancreatitis; pharmacoeconomics; direct cost; pancreatic enzyme replacement therapy; cost of illness.
Subjects: Departments at MU > Public Health
Medicine > KMC Manipal > Gastroenterology
Pharmacy > MCOPS Manipal > Pharmacy Practice
Depositing User: KMC Library
Date Deposited: 16 Aug 2019 08:39
Last Modified: 16 Aug 2019 08:39

Actions (login required)

View Item View Item